Interests and needs of eye care providers in clinical decision support for glaucoma. Issue 1 (15th January 2021)

• Record Type: Journal Article
• Authors: Stagg, Brian; Stein, Joshua D; Medeiros, Felipe A; Cummins, Mollie; Kawamoto, Kensaku; Hess, Rachel
• Is Part Of: BMJ open ophthalmology. Volume 6:Issue 1(2021)
• Publication Date: 2021-01-15
• Subjects: glaucoma -- epidemiology; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1136/bmjophth-2020-000639
• Languages: English
• ISSNs: 2397-3269

Abstract

Abstract : Objective: To study whether clinicians who treat glaucoma are interested in using clinical decision support (CDS) tools for glaucoma, what glaucoma clinical decisions they feel would benefit from CDS, and what characteristics of CDS design they feel would be important in glaucoma clinical practice. Methods and analysis: Working with the American Glaucoma Society, the Utah Ophthalmology Society and the Utah Optometric Association, we identified a group of clinicians who care for patients with glaucoma. We asked these clinicians about interest in CDS, what glaucoma clinical decisions would benefit from CDS, and what characteristics of CDS tool design would be important in glaucoma clinical practice. Results: Of the 105 clinicians (31 optometrists, 10 general ophthalmologists and 64 glaucoma specialists), 93 (88.6%) were either 'definitely' or 'probably' interested in using CDS for glaucoma. There were no statistically significant differences in interest between clinical specialties (p=0.12), years in practice (p=0.85) or numbers of patients seen daily (p=0.99). Identifying progression of glaucoma was the clinical decision the largest number of clinicians felt would benefit from CDS (104/105, 99.1%). An easy to use interface was the CDS characteristic the largest number of clinicians felt would be 'very important' (93/105, 88.6%). Conclusion: Of this group of clinicians who treat glaucoma, 88.6% were interested in using CDS for glaucoma and 99.1% felt that identification of glaucomatous progression could benefit from CDS. This level of interest supports future work to develop CDS for glaucoma.